ITOC-1 – 2014


The first edition of ITOC took place at the Ludwig-Maximilians-Universität in Munich, Germany and strived to provide a forum for discussion of early clinical drug development and address its unique challenges of drug development. The programme focused on topics such as immunomodulatory agents, anti-cancer vaccines and monoclonal antibodies with special emphasis on translational research and biomarker development.

Plenary Sessions

ITOC-1 presented plenary sessions on “Cancer Immunology”, “Targeting Immune Suppression”, “Stimulation of Immune Function”, “Therapeutic Anti-Cancer Vaccines”, “Monitoring of Immunotherapy”, “Adoptive Cell Therapy” and “Engineered T Cell Therapy”.

Keynote lectures were given by Prof. Alexander M.M. Eggermont, Institut Gustave Roussy (France) on Cancer immunotherapy-current and future advancements; Prof. Cristina Maccalli, San Raffaele Scientific and University Institute, on Imunobiological properties of the human cancer stem cells; Prof. James P. Allison, The University of Texas MD Anderson Cancer Center (USA), on Regulatory T cells and suppression of immune response; Prof. John E. Janik, Georgia Regent University Cancer Center (USA), on Vaccine development and Prof. Francesco M. Marincola, Sidra Medical and Research Center (Quatar),on Basic concept for the understanding of cancer mediated immune rejection.

Satellite Symposia and Poster Sessions

The scientific programme of ITOC-1 was completed with:

Two sponsored satellite sessions:

  • “Is Immuno-Oncology the next new paradigm in cancer treatment?”– Bristol-Myers Squibb
  • “Cancer immunotherapy: changing treatment paradigms in oncology”– F.Hoffmann-La Roche

Eight Poster Sessions which tackled topics such as“Monitoring of Immunotherapy”,“Immunomodulation”,“Vaccines”,“Immunocytokines”,“Combination therapy”, “Adoptive Immunotherapy”,“Engineered T-cell therapy”.

Poster Awards

The poster awards were sponsored by the Munich Tumour Center and given to:

  • Winner – M. Schnurr, Ludwig-Maximilians University, Munich, Germany. Poster : “RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells.”
  • Runner-up – D. Bund, University of Munich-Grosshadern, Munich, Germany. Poster : “Minor-histocompatibility-antigen UTY as target for graft-versus-leukaemia and graft-versus-haematopoiesis in the canine model.”
  • Third Place – M. Idorn, Herlev University Hospital, Herlev, Denmark. Poster :  “Genetic engineering of T cells for increased homing to the tumour site.” 

ITOC-1 Abstract Book


ITOC-1 General Information Flyer

itoc1-gen info

ITOC-1 Scientific Programme

  • The Final Scientific Programme of ITOC-1 is available as PDF here.

ITOC-1 Webcasts

  • You can see the interviews with some of ITOC-1 speakers here.